2017 Press Releases

2017 | 2016 | 2015 | 2014 | 2013 | 2012

AMAG and Palatin Announce Rekynda™ Data Presentations at the International Society for the Study of Women’s Sexual Health Annual Meeting

Both Phase 3 RECONNECT studies met co-primary endpoints and demonstrated significant improvement in key symptoms of hypoactive sexual desire disorder ... More > 

AMAG Reports Fourth Quarter and Full Year 2016 Financial Results

2016 GAAP revenue increased 27% over 2015 Achieved record quarterly and annual net sales for Makena® and Feraheme® Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass., Feb. 14, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today reported unaudited consolidated f... More > 

AMAG and Endoceutics Enter Into an Exclusive U.S. License Agreement for Intrarosa™ (Prasterone)

Recently approved first-of-its-kind, non-estrogen prescription therapy for a common symptom of menopause Conference call sch... More > 

AMAG Pharmaceuticals to Present at Upcoming Investor Conference

WALTHAM, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in an analyst-led fireside chat at the Leerink Partners Global Healthcare Conference on Thursday, February 16, 2017 at 2:00 p.m. EST. A live audio webcast ... More > 

AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2016 Financial Results Conference Call and Webcast on Tuesday, February 14, 2017 at 8:00 a.m. ET

WALTHAM, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it will report financial results for the fourth quarter and year ended December 31, 2016 on Tuesday, February 14, 2017 before the U.S. financial markets open. Management will host a conf... More > 

AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement for North American Rights to Rekynda™ (bremelanotide)

Anticipated new drug application (NDA) filing in early 2018 WALTHAM, Mass., Feb. 03, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced today the closing of the licensing agreement with Palatin Technologies, Inc. for exclusive North American commercial rights to RekyndaTM... More > 

AMAG Pharmaceuticals Announces Positive Topline Results from Definitive Pharmacokinetic Study for Makena Subcutaneous Administration

Supplemental new drug application on track for second quarter 2017 filing WALTHAM, Mass., Feb. 02, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced results from its definitive pharmacokinetic (PK) study designed to demonstrate comparable bioavailability of the sub... More > 

AMAG Pharmaceuticals Provides Financial and Business Update

2016 total revenue increased 45 percent Provides update on Makena® next-generation program Anticipates 2017 GAAP revenue of $620-$670 million, including Makena net sales of $410-$440 million WALTHAM, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today provi... More > 

AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekynda™ (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder

Two Phase 3 trials completed for Rekynda; co-primary endpoints met Will address underserved medical condition with significant untapped market potential Broadens AMAG’s presence in women’s health and leverages AMAG’s commercial capabilities and customer relationships WALTHAM, Mass. and CRANBURY... More > 

AMAG Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that William Heiden, chief executive officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time... More >